Molecular genetics of B-precursor acute lymphoblastic leukemia
Open accessThe DOI matches its Crossref record; 126 of the 127 references it cites were found in a registry or an index.
Abstract
B-precursor acute lymphoblastic leukemia (B-ALL) is the most common childhood tumor and the leading cause of cancer-related death in children and young adults. The majority of B-ALL cases are aneuploid or harbor recurring structural chromosomal rearrangements that are important initiating events in leukemogenesis but are insufficient to explain the biology and heterogeneity of disease. Recent studies have used microarrays and sequencing to comprehensively identify all somatic genetic alterations in acute lymphoblastic leukemia (ALL). These studies have identified cryptic or submicroscopic genetic alterations that define new ALL subtypes, cooperate with known chromosomal rearrangements, and influence prognosis. This article reviews these advances, discusses results from ongoing second-generation sequencing studies of ALL, and highlights challenges and opportunities for future genetic profiling approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“BCP-ALL, which is characterized by a block in lymphoid differentiation leading to the accumulation of immature progenitor cells.37”
From PELI2 regulates early B-cell progenitor differentiation and related leukemia via the IL-7R expression (2023) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“org Volume 122 Number 10 October 2012 3409 such as imatinib mesylate (Gleevec) have transformed the treatment and outcome of patients with BCR-ABL1–positive leukemia (40, 41).”
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713 · cited 1×
“org Volume 122 Number 10 October 2012 3409 such as imatinib mesylate (Gleevec) have transformed the treatment and outcome of patients with BCR-ABL1–positive leukemia (40, 41).”
Yeoh, E.-J., Ross, M. E., Shurtleff, S. A., Williams, W. K., Patel, D., Mahfouz, R., Behm, F. G., Raimondi, S. C., Relling, M. V., Patel, A., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00032-6 · Cited by 1,917 · cited 1×
“These approaches, coupled with candidate gene sequencing and integrated gene expression profiling (92), have identified a number of critical new targets of mutation in B-ALL that often involve genes that regulate lymphoid development, cell cycle, tumor suppression, and a variety of other key…”
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan-Smith, E., Dalton, J. D., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,801 · cited 6×
“The nature and frequency of these CNAs are significantly associated with ALL subtype, with few lesions in MLL-rearranged ALL (17, 55) but 6–8 lesions per case in BCR-ABL1 and ETV6-RUNX1 ALL (33, 34).”
InfluentialSelf-citationCBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596
Self-citationPui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422 · cited 2×
“Despite their high frequency of occurrence, PAX5 alterations are not associated with outcome in ALL (81, 95).”
Self-citation
Research works printed but not linked: 2
- Andersson AK, et al. Whole genome sequence anal- ysis of 22 MLL rearranged infant acute lympho- blastic leukemias reveals remarkably few somatic mutations: a report from the St. Jude Children's Research Hospital -Washington University Pedi- atric Cancer Genome Project. ASH Annual Meeting Abstracts. 2011;118:69.
- Mullighan, 2007, 110, 691
Cited by
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Self-citationGokbuget, N., Dombret, H., Ribera, J.-M., Fielding, A. K., Advani, A., Bassan, R., Chia, V., Doubek, M., Giebel, S., Hoelzer, D., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.144311 · Cited by 227
“50 In 3 salvage Without prior HSCT 12/108 11 (6, 19) 108 2.”
Oshima, K., Khiabanian, H., da Silva-Almeida, A. C., Tzoneva, G., Abate, F., Ambesi-Impiombato, A., Sanchez-Martin, M., Carpenter, Z., Penson, A., Perez-Garcia, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608420113 · Cited by 194
“Recurrently somatically mutated genes in our series included known oncogenes and tumor suppressors mutated in B-cell precursor ALL [KRAS, NRAS, Fms related tyrosine kinase 3 (FLT3), Janus kinase 2 (JAK2), Janus kinase 3 (JAK3), and CREBBP] (20) and T-cell ALL [Notch1 (NOTCH1), FBXW7, PHF6, DNM2, WT1, JAK1, JAK3, BCL11…”
BackgroundGenomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia
Lim, J. Y., Bhatia, S., Robison, L. L., & Yang, J. J. (2014) · Cancer · doi:10.1002/cncr.28531 · Cited by 180
“Recent high-throughput genomic profiling of ALL (eg, genomewide gene expression, DNA copy number, and single nucleotide polymorphism [SNP] genotype) has dramatically improved our understanding of the genetic landscape of this disease and has also led to the discovery of novel molecular markers for treatment individual…”
BackgroundPalanichamy, J. K., Tran, T. M., Howard, J. M., Contreras, J. R., Fernando, T. R., Sterne-Weiler, T., Katzman, S., Toloue, M., Yan, W., Basso, G., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80046 · Cited by 168
“org Volume 126 Number 4 April 2016 Introduction Oncogenesis in early B cell progenitors results in B cell acute lymphoblastic leukemia (B-ALL), the most prevalent hematological neoplasm in children and young adults (1).”
Background
Metadata
- Authors
- Mullighan, C. G.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Corresponding author
- Mullighan, Charles G.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-10-01
- Volume
- 122
- Issue
- 10
- Pages
- 3407-3415
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3461902
- OpenAlex
- W2146473098
- Cited by
- 247
- References
- 127
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 12 · 2023: 10 · 2022: 15 · 2021: 17 · 2020: 22 · 2019: 21 · 2018: 15 · 2017: 30 · 2016: 32 · 2015: 16 · 2014: 20 · 2013: 17 · 2012: 1
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- American Society of Hematology
- St. Jude Children's Research Hospital
- American Lebanese Syrian Associated Charities (38105)
- Children’s Oncology Group
- Stand Up To Cancer
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Keywords
- B-cell precursor acute lymphoblastic leukemia, somatic alterations, chromosomal rearrangements, aneuploidy, prognosis, leukemogenesis, genetic profiling, childhood cancer
- MeSH terms
- Adult, Animals, B-Lymphocytes, Child, Clone Cells, Hematopoietic Stem Cells, Humans, Neoplasm Proteins, Prognosis, Risk, Translocation, Genetic, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Oncogene Proteins, Fusion, Mice, Knockout, Cell Lineage, Genetic Predisposition to Disease, Gene Expression Profiling, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular genetics of B-precursor acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1172/jci61203
- The paper
- Mullighan, C. G. (2012). Molecular genetics of B-precursor acute lymphoblastic leukemia. Journal of Clinical Investigation. https://doi.org/10.1172/jci61203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.